Lantheus (NASDAQ:LNTH) stock rose ~17% on Thursday after Q4 results beat estimates and the FY23 outlook was placed above expectations.
Q4 adjuested EPS grew +448% Y/Y to $1.37, while revenues increased +103% to $263.17M. Both top and bottom line numbers surpassed analysts expectations.
“2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. We accelerated our growth, diversified our portfolio, and delivered record revenues and profits which created additional free cash flows,” said Lantheus President and CEO Mary Anne Heino.
Truist, which has a Buy rating on LNTH, noted that the imaging agent Pylarify exceeded expectations.
Analyst Richard Newitter added that Lantheus saw another impressive margin beat which helped to drive EPS upside and guided to Adjusted EPS between $4.95 and $5.10 versus the firm’s estimate of our $4.30, which it sees as implying margin upside and anticipates that EPS and margin estimates will continue to move higher, according to a Bloomberg note.
Meanwhile SVB Securities Analyst Roanna Ruiz noted that the FY2023 outlook is strong and highlights Pylarify’s solid growth in Q4.
Ruiz added that the firms expects that Lantheus’ commercial and late-stage clinical portfolio should help attractive longer-term revenue and EPS growth and margin expansion.
SVB Securities has an Outperform rating on LNTH. The SA Quant Rating on Lantheus stock is Buy, while the average Wall Street Analysts’ Rating is Strong Buy.
Q1: The company expects Q1 2023 revenue to be between $280M and $285M (consensus $256.47M). Q1 2023 Adjusted EPS is anticipated in the range of $1.28 to $1.32 (consensus $1.06).
Full year 2023: Lantheus expects FY23 revenue in the range of $1.14B to $1.16B (consensus $1.04B). The company anticipates FY23 adjusted EPS between $4.95 and $5.10 (consensus $4.22).